Quadrature Capital
TSHA icon

Quadrature Capital’s Taysha Gene Therapies TSHA Stock Holding History

Quadrature Capital’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$175K Buy
25,753
+2,254
+10% +$13.3K ﹤0.01% 1383
2026
Q1 		$105K Buy
+23,499
New +$109K ﹤0.01% 1218
2025
Q4 		– Sell
-47,328
Closed -$154K – 1657
2025
Q3 		$154K Sell
47,328
-114,612
-71% -$325K ﹤0.01% 825
2025
Q2 		$373K Buy
+161,940
New +$352K 0.01% 635

Other funds holding TSHA

Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Quadrature Capital's TSHA Position: Q2 2026 in Review

Quadrature Capital increased its Taysha Gene Therapies (TSHA) stake by 9.6% in Q2 2026, buying an estimated $13.3K and bringing the position to 25,753 shares worth $175K. The position accounts for ﹤0.01% of the portfolio, ranked #1383.

Quadrature Capital first reported a position in TSHA in Q2 2025 and has held it in 4 quarters since. The position peaked at $373K in Q2 2025. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Quadrature Capital held 25,753 shares of Taysha Gene Therapies worth $175K as of Q2 2026.
  • Quadrature Capital bought 2,254 Taysha Gene Therapies shares in Q2 2026, an estimated $13.3K.
  • Taysha Gene Therapies made up ﹤0.01% of Quadrature Capital's portfolio in Q2 2026, its #1383 holding.
  • Quadrature Capital first reported a position in Taysha Gene Therapies in Q2 2025 and has held it in 4 quarters since.
  • Quadrature Capital's Taysha Gene Therapies position peaked at $373K in Q2 2025.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.